Mogam Institute for Biomedical Research

The Green Cross Corporation

Mogam Biotechnology Research Institute

Dana-farber-cancer Institute Inc.

Mogam Biotechnology Institute

Hyung-Kwon Lim

Dong-Sik Kim

Young Seoub Park

Jae Hyun Park

Kisu Kim

Sujeong Kim

Soongyu Choi

Kyuhyun Lee

Mijung Lee

Eun Jung Song

Eun-Hee Lee

Jongwha Won

Jae-chan Park

Mi Jung Lee

Jung Hwan Park

Hyo Jung Nam

Sung-Geun Kim

Jae Chan Park

Ki Joon Cho

Miyoung Oh

Hye-Ji Choi

Yeup Yoon

Sumin Lee

Heechun Kwak

Sung Geun Kim

Junhong Jeong

SungHo Hwang

Jae-Chan Park

Sungho Hwang

Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.

Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Anti-mesothelin antibody and composition comprising the same

The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Anti-glypican 3 antibody and pharmaceutical composition containing the same

The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Antibody binding to TFPI and composition comprising the same

There are provided a method named Tat-associated protein engineering (TAPE), of screening a target protein having higher solubility and excellent thermostability, in particular, an immunoglobulin variable domain (VH or VL) derived from human germ cells, by preparing a gene construct where the target protein and an antibiotic-resistant protein are linked to a Tat signal sequence, and then expressing this within, and human or engineered VH and VL domain antibodies and human or engineered VH and VL domain antibody scaffolds having solubility and excellent thermostability, which are screened by the TAPE method. There are also provided a library including random CDR sequences in the human or engineered VH or VL domain antibody scaffold screened by the TAPE method, and a preparing method thereof. There are also provided a VH or VL domain antibody having binding ability to the target protein screened by using the library, and a pharmaceutical composition including the domain antibody.

Screening and engineering method of super-stable immunoglobulin variable domains and their uses

Provided is a method for improving secretion efficiency of a recombinant foreign protein in a yeast expression system. The method includes transforming a yeast host with a recombinant foreign gene construct containing a galactose-inducible promoter, a secretion signal sequence and a gene encoding the foreign protein to construct a transformed yeast strain; and culturing the transformed yeast strain under the condition that the activity of the galactose-inducible promoter is controlled. Improved secretion efficiency of the foreign protein can be achieved by decreasing overexpression-induced insoluble precipitation of the recombinant foreign protein suffered by a conventional galactose-inducible promoter-based yeast expression system, via appropriate control of a level of galactose functioning as an inducer of the galactose-inducible promoter in cells. Due to improved secretion efficiency of the recombinant foreign protein, present invention makes a contribution to improvement in productivity of recombinant foreign proteins in the yeast expression system and reduction in production costs.

Methods for enhancing a secretion efficiency of recombinant foreign protein in yeast expression system

The present invention relates to a method for preparing LK8 protein, more precisely, a method for mass-production of LK8 protein usingtransformed by a gene coding LK8 protein having angiogenesis inhibiting activity. The transformed strain of the present invention and production processes of LK8 protein are expected to contribute greatly to the commercialization of LK8 protein as a novel angiogenesis inhibitor.

[object Object]

Growing community of inventors

Yongin-si, South Korea

Hyung-Kwon Lim